Prostate cancer (PC) is the second-most frequently diagnosed cancer in men worldwide,
with 1.1 million new cases estimated to have occurred in 2012. Chemoprevention, prostate …

Prostate cancer is the most commonly diagnosed cancer and the second most common
cause of cancer-related death in men, and benign prostatic hyperplasia is the most common …

Prostate cancer is a significant public health burden and one of the most common cancers
globally and in the United States. The current cornerstone of prostate cancer systemic …

This review focuses on significant recent findings regarding modulators of androgen and
estrogen receptor activity. Selective androgen receptor modulators (SARMs) interact with …

Prostate cancer is androgen-dependent, and hormone therapy, mainly achieved by
androgen deprivation, has been one of the main treatment modalities in the clinical …

Introduction Prostate cancer is the most common solid organ malignancy in men in the
United States. Until recently, treatment options for men with metastatic disease were limited …

Prostate cancer is a substantial public health burden and a leading cause of cancer—
related morbidity and mortality in the United States despite the observation that annual …

The major androgen within the prostate is dihydrotestosterone (DHT). DHT and 5α-
reductase are highly associated with prostate cancer. It has been hypothesised that …

Use of exogenous estrogens in manipulating the androgenestrogen equilibrium was one of
the earliest therapeutic strategies developed to treat prostate cancer which followed close …

The burden of prostate cancer (PCa) in the world is significant; PCa remains the most
frequently diagnosed noncutaneous malignancy and remains the second leading cause of …